v3.23.2
Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Revenue $ 8,312,100,000 $ 6,488,000,000 $ 15,272,100,000 $ 14,298,000,000
U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 5,531,400,000 3,934,800,000 9,967,600,000 9,109,400,000
Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 2,780,700,000 2,553,300,000 5,304,600,000 5,188,700,000
Diabetes        
Disaggregation of Revenue [Line Items]        
Revenue 5,010,900,000 3,438,200,000 9,201,300,000 6,826,300,000
Diabetes | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 3,781,400,000 2,292,200,000 6,856,400,000 4,568,700,000
Diabetes | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,229,500,000 1,146,000,000 2,344,900,000 2,257,600,000
Trulicity®        
Disaggregation of Revenue [Line Items]        
Revenue 1,812,500,000 1,911,900,000 3,789,600,000 3,653,200,000
Trulicity® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,371,300,000 1,430,100,000 2,918,700,000 2,744,100,000
Trulicity® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 441,200,000 481,700,000 871,000,000.0 909,100,000
Mounjaro®        
Disaggregation of Revenue [Line Items]        
Revenue 979,700,000 16,000,000.0 1,548,200,000 16,000,000.0
Mounjaro® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 915,700,000 12,600,000 1,452,200,000 12,600,000
Mounjaro® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 64,000,000.0 3,400,000 96,000,000.0 3,400,000
Jardiance        
Disaggregation of Revenue [Line Items]        
Revenue 668,300,000 461,000,000.0 1,245,800,000 880,400,000
Jardiance | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 386,100,000 250,700,000 715,600,000 480,400,000
Jardiance | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 282,200,000 210,300,000 530,200,000 400,000,000.0
Baqsimi        
Disaggregation of Revenue [Line Items]        
Revenue 613,900,000 29,000,000.0 645,400,000 58,200,000
Baqsimi | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 606,200,000 21,800,000 629,300,000 44,300,000
Baqsimi | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 7,700,000 7,200,000 16,100,000 13,900,000
Humalog®        
Disaggregation of Revenue [Line Items]        
Revenue 440,400,000 447,100,000 901,400,000 1,065,300,000
Humalog® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 229,800,000 238,800,000 501,400,000 607,700,000
Humalog® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 210,600,000 208,300,000 400,000,000.0 457,600,000
Humulin®        
Disaggregation of Revenue [Line Items]        
Revenue 205,300,000 274,000,000.0 457,300,000 547,200,000
Humulin® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 144,300,000 202,300,000 343,100,000 392,800,000
Humulin® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 61,000,000.0 71,700,000 114,200,000 154,500,000
Basaglar®        
Disaggregation of Revenue [Line Items]        
Revenue 154,200,000 174,200,000 363,500,000 365,700,000
Basaglar® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 83,000,000.0 95,800,000 218,400,000 215,100,000
Basaglar® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 71,200,000 78,400,000 145,200,000 150,600,000
Other diabetes        
Disaggregation of Revenue [Line Items]        
Revenue 136,600,000 125,000,000.0 250,100,000 240,300,000
Other diabetes | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 45,000,000.0 40,100,000 77,700,000 71,700,000
Other diabetes | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 91,600,000 85,000,000.0 172,200,000 168,500,000
Oncology        
Disaggregation of Revenue [Line Items]        
Revenue 1,671,000,000 1,368,700,000 3,027,000,000 2,721,700,000
Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 935,000,000.0 819,000,000.0 1,688,400,000 1,602,700,000
Oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 736,000,000.0 549,800,000 1,338,600,000 1,119,000,000
Verzenio®        
Disaggregation of Revenue [Line Items]        
Revenue 926,800,000 588,500,000 1,677,700,000 1,057,900,000
Verzenio® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 588,600,000 384,300,000 1,049,600,000 685,700,000
Verzenio® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 338,200,000 204,200,000 628,000,000.0 372,100,000
Cyramza®        
Disaggregation of Revenue [Line Items]        
Revenue 260,300,000 231,300,000 497,000,000.0 461,500,000
Cyramza® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 115,000,000.0 92,600,000 215,600,000 171,800,000
Cyramza® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 145,300,000 138,600,000 281,400,000 289,700,000
Erbitux®        
Disaggregation of Revenue [Line Items]        
Revenue 162,500,000 140,800,000 292,400,000 263,400,000
Erbitux® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 145,500,000 125,100,000 264,200,000 234,700,000
Erbitux® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 17,000,000.0 15,700,000 28,100,000 28,700,000
Alimta®        
Disaggregation of Revenue [Line Items]        
Revenue 60,900,000 227,700,000 119,100,000 571,700,000
Alimta® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 17,900,000 171,700,000 38,000,000.0 425,900,000
Alimta® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 43,100,000 56,100,000 81,200,000 145,800,000
Other oncology        
Disaggregation of Revenue [Line Items]        
Revenue 260,500,000 180,400,000 440,800,000 367,200,000
Other oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 68,000,000.0 45,300,000 121,000,000.0 84,600,000
Other oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 192,400,000 135,200,000 319,900,000 282,700,000
Immunology        
Disaggregation of Revenue [Line Items]        
Revenue 928,500,000 796,500,000 1,706,300,000 1,544,600,000
Immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 523,100,000 422,000,000.0 877,600,000 800,500,000
Immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 405,400,000 374,500,000 828,600,000 744,100,000
Taltz®        
Disaggregation of Revenue [Line Items]        
Revenue 703,900,000 606,200,000 1,230,800,000 1,094,300,000
Taltz® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 472,300,000 411,600,000 784,500,000 718,800,000
Taltz® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 231,600,000 194,700,000 446,300,000 375,500,000
Olumiant®        
Disaggregation of Revenue [Line Items]        
Revenue 218,900,000 186,200,000 447,800,000 441,800,000
Olumiant® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 50,800,000 10,400,000 93,100,000 81,700,000
Olumiant® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 168,100,000 175,800,000 354,600,000 360,100,000
Other immunology        
Disaggregation of Revenue [Line Items]        
Revenue 5,700,000 4,000,000.0 27,700,000 8,500,000
Other immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 0 0 0 0
Other immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 5,700,000 4,000,000.0 27,700,000 8,500,000
Neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 387,200,000 389,900,000 747,700,000 787,700,000
Neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 160,900,000 144,800,000 305,400,000 298,100,000
Neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 226,300,000 245,200,000 442,300,000 489,500,000
Emgality®        
Disaggregation of Revenue [Line Items]        
Revenue 169,300,000 157,500,000 323,600,000 306,700,000
Emgality® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 118,800,000 108,600,000 227,500,000 216,900,000
Emgality® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 50,500,000 48,900,000 96,100,000 89,800,000
Other neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 217,900,000 232,400,000 424,100,000 481,000,000.0
Other neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 42,100,000 36,200,000 77,900,000 81,200,000
Other neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 175,800,000 196,300,000 346,200,000 399,700,000
Other        
Disaggregation of Revenue [Line Items]        
Revenue 314,600,000 494,700,000 589,900,000 2,417,700,000
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 131,000,000.0 256,900,000 239,800,000 1,839,200,000
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 183,500,000 237,900,000 350,100,000 578,500,000
Forteo®        
Disaggregation of Revenue [Line Items]        
Revenue 148,000,000.0 138,500,000 270,300,000 275,900,000
Forteo® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 97,400,000 78,500,000 168,000,000.0 148,700,000
Forteo® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 50,600,000 60,000,000.0 102,300,000 127,200,000
Cialis®        
Disaggregation of Revenue [Line Items]        
Revenue 115,600,000 147,000,000.0 215,900,000 364,700,000
Cialis® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 9,200,000 10,800,000 16,800,000 17,700,000
Cialis® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 106,400,000 136,200,000 199,100,000 347,000,000.0
COVID-19 antibodies        
Disaggregation of Revenue [Line Items]        
Revenue 0 129,100,000 0 1,598,900,000
COVID-19 antibodies | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 0 129,100,000 0 1,584,300,000
COVID-19 antibodies | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 0 0 0 14,700,000
Other        
Disaggregation of Revenue [Line Items]        
Revenue 51,000,000.0 80,100,000 103,700,000 178,200,000
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 24,400,000 38,500,000 55,000,000.0 88,500,000
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue $ 26,500,000 $ 41,700,000 $ 48,700,000 $ 89,600,000